Precision BioSciences, Inc. announced that Stanley R. Frankel, M.D. has been appointed as a Director on the Company’s Board of Directors and a member of the Board’s Science and Technology (S&T) Committee. Dr. Frankel is a hematologist-oncologist with extensive academic and industry experience in the research, clinical development, and commercialization of immuno-oncology and cellular therapies. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies including acute lymphoblastic leukemia, multiple myeloma, and lymphoma. Dr. Frankel was most recently the Senior Vice President, Cellular Therapy Development at Bristol-Myers Squibb (BMS) where he was responsible for late development portfolio of cellular therapy assets including Breyanzi® (lisocabtagene maraleucel) and Abecma® (idecabtagene vicleucel). Prior to the BMS acquisition of Celgene, he was Corporate Vice President, Head, Immuno-Oncology & Cellular Therapy, Clinical Research and Development Head, Cell Therapy Clinical Center of Excellence at Celgene. Additionally, Tony Yao M.D., Ph.D, a member of Precision’s Board of Directors will continue to serve until his term concludes at the upcoming 2021 stockholders meeting on May 10, 2021. Dr. Yao has served on Precision’s Board, including its Nominating and Corporate Governance Committee, since April 2018. Dr. Yao also chaired the S&T Committee since it was formed in 2020.